董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Clay B. Thorp | 男 | Chairman | 51 | 未披露 | 未持股 | 2018-09-15 |
| Peter Justin Klein | 男 | Director | 41 | 未披露 | 未持股 | 2018-09-15 |
| Jonathan P. Mow | 男 | Chief Executive Officer and Director | 53 | 43.62万美元 | 未持股 | 2018-09-15 |
| Clay B. Thorp | 男 | Chairman | 51 | 未披露 | 未持股 | 2018-09-15 |
| Nancy J. Hutson | -- | Director | 69 | 未披露 | 未持股 | 2018-09-15 |
| Peter Justin Klein | 男 | Director | 41 | 未披露 | 未持股 | 2018-09-15 |
| Caroline Loewy | 女 | Director | 51 | 未披露 | 未持股 | 2018-09-15 |
| Bibhash Mukhopadhyay | 男 | Director | 37 | 未披露 | 未持股 | 2018-09-15 |
| Tyrell Rivers | 男 | Director | 45 | 未披露 | 未持股 | 2018-09-15 |
| Linda Tufts | 女 | Director | 64 | 未披露 | 未持股 | 2018-09-15 |
| Nancy J. Hutson | 女 | Director | 69 | 未披露 | 未持股 | 2018-09-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan P. Mow | 男 | Chief Executive Officer and Director | 53 | 43.62万美元 | 未持股 | 2018-09-15 |
| Susan Arnold | -- | Vice President, Preclinical and Chemistry, Manufacturing and Controls | 43 | 未披露 | 未持股 | 2018-09-15 |
| James Ballance | 男 | Vice President, Research and Scientific Affairs | 59 | 未披露 | 未持股 | 2018-09-15 |
| John Lee | 男 | Chief Medical Officer | 50 | 37.04万美元 | 未持股 | 2018-09-15 |
| Michael York | 男 | Vice President, Corporate Development and Commercial Strategy | 53 | 未披露 | 未持股 | 2018-09-15 |
| John Sharp | 男 | Chief Financial Officer | 53 | 36.81万美元 | 未持股 | 2018-09-15 |
董事简历
中英对照 | 中文 | 英文- Clay B. Thorp
-
Clay B. Thorp，与他人共同创立并担任投资公司Hatteras Venture Partners的普通合伙人，在那里他领导对生物制药、医疗器械、诊断和研究信息学领域的一系列生命科学公司的投资。此前，他在几家生命科学公司的创立中发挥了重要作用，包括担任Synthematix，Inc.的联合创始人、首席执行官和董事长，该公司是一家化学信息学公司，于2005年被Symyx Technologies收购，是PhaseBio制药公司的联合创始人和前董事长，Novalon Pharmaceutical Corporation的联合创始人和企业发展负责人，该公司于2000年被出售给Karo Bio，Xanthon，Inc.的联合创始人和总裁，Xanthon，Inc.是一家拥有直接分析DNA、RNA和蛋白质的电化学检测技术的生物信息学公司。Thorp先生拥有哈佛大学公共政策硕士学位和北卡罗来纳大学教堂山分校数学和历史学士学位。
Clay B. Thorp,co-founded and has since served as General Partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. Previously, he was instrumental in the founding of several life sciences companies, including serving as co-founder, Chief Executive Officer and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005 co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc., co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000 and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp holds a Masters of Public Policy degree from Harvard University and a B.A. degree in Mathematics and History from the University of North Carolina at Chapel Hill. - Clay B. Thorp，与他人共同创立并担任投资公司Hatteras Venture Partners的普通合伙人，在那里他领导对生物制药、医疗器械、诊断和研究信息学领域的一系列生命科学公司的投资。此前，他在几家生命科学公司的创立中发挥了重要作用，包括担任Synthematix，Inc.的联合创始人、首席执行官和董事长，该公司是一家化学信息学公司，于2005年被Symyx Technologies收购，是PhaseBio制药公司的联合创始人和前董事长，Novalon Pharmaceutical Corporation的联合创始人和企业发展负责人，该公司于2000年被出售给Karo Bio，Xanthon，Inc.的联合创始人和总裁，Xanthon，Inc.是一家拥有直接分析DNA、RNA和蛋白质的电化学检测技术的生物信息学公司。Thorp先生拥有哈佛大学公共政策硕士学位和北卡罗来纳大学教堂山分校数学和历史学士学位。
- Clay B. Thorp,co-founded and has since served as General Partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. Previously, he was instrumental in the founding of several life sciences companies, including serving as co-founder, Chief Executive Officer and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005 co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc., co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000 and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp holds a Masters of Public Policy degree from Harvard University and a B.A. degree in Mathematics and History from the University of North Carolina at Chapel Hill.
- Peter Justin Klein
-
Peter Justin Klein于2015年12月被选为公司董事。Klein从2013年9月到2015年12月担任Senseonics, Incorporated董事。Klein自2006年起担任NEA合伙人。加入NEA之前，Klein在Duke University Health System任职。Klein现任多个私营生命科学公司董事。Klein持有Duke University文学学士、理学学士和理学硕士学位；Harvard Law School法律博士学位。
Peter Justin Klein was elected to our Board of Directors in December 2015. Dr. Klein served on the Senseonics, Incorporated Board of Directors from September 2013 to December 2015. Dr. Klein has served as a Partner at NEA since 2006. Prior to joining NEA, Dr. Klein worked for the Duke University Health System. Dr. Klein currently serves as a director of several private life sciences companies. Dr. Klein received his A.B., B.S. and M.D. from Duke University and his J.D. from Harvard Law School. - Peter Justin Klein于2015年12月被选为公司董事。Klein从2013年9月到2015年12月担任Senseonics, Incorporated董事。Klein自2006年起担任NEA合伙人。加入NEA之前，Klein在Duke University Health System任职。Klein现任多个私营生命科学公司董事。Klein持有Duke University文学学士、理学学士和理学硕士学位；Harvard Law School法律博士学位。
- Peter Justin Klein was elected to our Board of Directors in December 2015. Dr. Klein served on the Senseonics, Incorporated Board of Directors from September 2013 to December 2015. Dr. Klein has served as a Partner at NEA since 2006. Prior to joining NEA, Dr. Klein worked for the Duke University Health System. Dr. Klein currently serves as a director of several private life sciences companies. Dr. Klein received his A.B., B.S. and M.D. from Duke University and his J.D. from Harvard Law School.
- Jonathan P. Mow
-
JonathanP.Mow自2014年9月以来一直担任我们的首席执行官兼董事会成员。他此前曾担任我们的首席商务官（2012年12月至2014年9月）。Mow先生在加州大学伯克利分校（University of California，Berkeley）获得机械工程学士学位，并在卡内基梅隆大学（Carnegie Mellon University）获得工商管理硕士学位。
Jonathan P. Mow has served as our Chief Executive Officer and a member of our board of directors since September 2014. He previously served as our Chief Business Officer from December 2012 to September 2014. Mr. Mow received a B.S. in mechanical engineering from the University of California, Berkeley and a M.B.A. from Carnegie Mellon University. - JonathanP.Mow自2014年9月以来一直担任我们的首席执行官兼董事会成员。他此前曾担任我们的首席商务官（2012年12月至2014年9月）。Mow先生在加州大学伯克利分校（University of California，Berkeley）获得机械工程学士学位，并在卡内基梅隆大学（Carnegie Mellon University）获得工商管理硕士学位。
- Jonathan P. Mow has served as our Chief Executive Officer and a member of our board of directors since September 2014. He previously served as our Chief Business Officer from December 2012 to September 2014. Mr. Mow received a B.S. in mechanical engineering from the University of California, Berkeley and a M.B.A. from Carnegie Mellon University.
- Clay B. Thorp
-
暂无中文简介
Clay B. Thorp co-founded our company in 2002 and has served as a member of our board of directors since that time. Mr. Thorp has served as chairman of our board of directors since November 2014. In 2001 Mr. Thorp co-founded and has since served as general partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. He has served on the board of directors of Clearside Biomedical, Inc. since January 2012. Previously, he helped found several life sciences companies, including serving as co-founder, chief executive officer and chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005 co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000 and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp received a B.A. in mathematics and history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University. -
暂无中文简介
- Clay B. Thorp co-founded our company in 2002 and has served as a member of our board of directors since that time. Mr. Thorp has served as chairman of our board of directors since November 2014. In 2001 Mr. Thorp co-founded and has since served as general partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. He has served on the board of directors of Clearside Biomedical, Inc. since January 2012. Previously, he helped found several life sciences companies, including serving as co-founder, chief executive officer and chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005 co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000 and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp received a B.A. in mathematics and history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University.
- Nancy J. Hutson
-
NancyJ.Hutson自2018年3月以来一直担任我们的董事会成员。Hutson博士于2006年退休，担任辉瑞公司（Pfizer，Inc.）全球研究与开发高级副总裁。Hutson博士自2012年1月起担任BioCrystPharmaceuticals，Inc.董事会成员，自2014年2月起担任制药公司Endo International plc董事会成员。Hutson博士曾于2008年1月至2014年12月被默克制药公司收购期间担任生物制药公司CubistPharmaceuticals，Inc.的董事会成员。Hutson博士在伊利诺伊卫斯理大学（Illinois Wesleyan University）获得普通生物学学士学位，并在范德堡大学（Vanderbilt University）获得生理学和生物化学博士学位。
Nancy J. Hutson has served as a member of our board of directors since March 2018. Dr. Hutson retired in 2006 as the senior vice president of global research and development at Pfizer, Inc. Dr. Hutson has served on the boards of directors of BioCryst Pharmaceuticals, Inc. since January 2012 and Endo International plc, a pharmaceutical company, since February 2014. Dr. Hutson previously served on the board of directors of Cubist Pharmaceuticals, Inc., a biopharmaceutical company, from January 2008 until it was acquired by Merck & Co., Inc. in December 2014. Dr. Hutson received a B.A. in general biology from Illinois Wesleyan University and a Ph.D. in physiology and biochemistry from Vanderbilt University. - NancyJ.Hutson自2018年3月以来一直担任我们的董事会成员。Hutson博士于2006年退休，担任辉瑞公司（Pfizer，Inc.）全球研究与开发高级副总裁。Hutson博士自2012年1月起担任BioCrystPharmaceuticals，Inc.董事会成员，自2014年2月起担任制药公司Endo International plc董事会成员。Hutson博士曾于2008年1月至2014年12月被默克制药公司收购期间担任生物制药公司CubistPharmaceuticals，Inc.的董事会成员。Hutson博士在伊利诺伊卫斯理大学（Illinois Wesleyan University）获得普通生物学学士学位，并在范德堡大学（Vanderbilt University）获得生理学和生物化学博士学位。
- Nancy J. Hutson has served as a member of our board of directors since March 2018. Dr. Hutson retired in 2006 as the senior vice president of global research and development at Pfizer, Inc. Dr. Hutson has served on the boards of directors of BioCryst Pharmaceuticals, Inc. since January 2012 and Endo International plc, a pharmaceutical company, since February 2014. Dr. Hutson previously served on the board of directors of Cubist Pharmaceuticals, Inc., a biopharmaceutical company, from January 2008 until it was acquired by Merck & Co., Inc. in December 2014. Dr. Hutson received a B.A. in general biology from Illinois Wesleyan University and a Ph.D. in physiology and biochemistry from Vanderbilt University.
- Peter Justin Klein
-
暂无中文简介
Peter Justin Klein has served as a member of our board of directors since December 2009. Dr. Klein currently serves as a partner at New Enterprise Associates, Inc., a venture capital firm, a position he has held since February 2012. He has served on the board of directors of Senseonics Holdings, Inc., a medical technology company, since December 2015. Dr. Klein received an A.B. in economics and a B.S. in biological anthropology and anatomy from Duke University, a J.D. from Harvard Law School and a M.D. from Duke University. -
暂无中文简介
- Peter Justin Klein has served as a member of our board of directors since December 2009. Dr. Klein currently serves as a partner at New Enterprise Associates, Inc., a venture capital firm, a position he has held since February 2012. He has served on the board of directors of Senseonics Holdings, Inc., a medical technology company, since December 2015. Dr. Klein received an A.B. in economics and a B.S. in biological anthropology and anatomy from Duke University, a J.D. from Harvard Law School and a M.D. from Duke University.
- Caroline Loewy
-
Caroline Loewy自2018年7月以来一直是我们的董事会成员。Loewy女士是为生物制药公司提供战略咨询服务的顾问，她自2014年2月以来一直担任该职位。她是Achieve Life Sciences的联合创始人，并于2015年9月至2017年8月被Oncogenex Pharmaceuticals，Inc.收购期间担任其首席商务官兼首席财务官。Loewy女士曾于2012年9月至2014年2月担任Tobira Therapeutics的首席财务官。Loewy女士自2016年12月起担任Cymabay Therapeutics的董事会成员，自2018年4月起担任Aptose Biosciences的董事会成员。Loewy女士在加州大学伯克利分校（University of California，Berkeley）获得文学学士学位，在卡内基梅隆大学（Carnegie Mellon University）获得工商管理硕士/硕士学位。
Caroline Loewy will serve as an independent director immediately upon the effective date of this prospectus. Ms. Loewy serves on public company boards, provides strategic advisory services to life science companies, and has more than 25 years of experience in the biopharmaceutical industry. From January 2021 to August 2021 Ms. Loewy served as a director of LWAC. She co-founded and served as Chief Financial Officer and Chief Business Officer of Achieve Life Sciences, Inc., a specialty pharmaceuticals company, from 2015 to 2017. Prior to Achieve Life Sciences, she served as Chief Financial Officer of several life sciences companies, including Tobira Therapeutics, Inc. from 2012 to 2014 Corcept Therapeutics Inc. from 2008 to 2011 and Poniard Pharmaceuticals, Inc. from 2006 to 2008. Prior to that, Ms. Loewy was a senior biotechnology equity research analyst at Morgan Stanley, Inc. from 2000 to 2004 and Prudential Securities, Inc. from 1996 to 1999. She began her career as a financial analyst at BankAmerica Corporation. Ms. Loewy is a founding board member of the Global Genes Project and a member of the Steering Committee of the Forum for Collaborative Research in Rare Diseases. She is also a founding board member of the KCNQ2 Cure Alliance Foundation. Ms. Loewy currently serves on the boards of directors of, Zogenix, Inc., CymaBay Therapeutics Inc., Aptose Biosciences Inc. and PhaseBio Pharmaceuticals, Inc. Ms. Loewy holds a B.A. from the University of California, Berkeley, and a M.B.A./M.S. degree from Carnegie Mellon University. - Caroline Loewy自2018年7月以来一直是我们的董事会成员。Loewy女士是为生物制药公司提供战略咨询服务的顾问，她自2014年2月以来一直担任该职位。她是Achieve Life Sciences的联合创始人，并于2015年9月至2017年8月被Oncogenex Pharmaceuticals，Inc.收购期间担任其首席商务官兼首席财务官。Loewy女士曾于2012年9月至2014年2月担任Tobira Therapeutics的首席财务官。Loewy女士自2016年12月起担任Cymabay Therapeutics的董事会成员，自2018年4月起担任Aptose Biosciences的董事会成员。Loewy女士在加州大学伯克利分校（University of California，Berkeley）获得文学学士学位，在卡内基梅隆大学（Carnegie Mellon University）获得工商管理硕士/硕士学位。
- Caroline Loewy will serve as an independent director immediately upon the effective date of this prospectus. Ms. Loewy serves on public company boards, provides strategic advisory services to life science companies, and has more than 25 years of experience in the biopharmaceutical industry. From January 2021 to August 2021 Ms. Loewy served as a director of LWAC. She co-founded and served as Chief Financial Officer and Chief Business Officer of Achieve Life Sciences, Inc., a specialty pharmaceuticals company, from 2015 to 2017. Prior to Achieve Life Sciences, she served as Chief Financial Officer of several life sciences companies, including Tobira Therapeutics, Inc. from 2012 to 2014 Corcept Therapeutics Inc. from 2008 to 2011 and Poniard Pharmaceuticals, Inc. from 2006 to 2008. Prior to that, Ms. Loewy was a senior biotechnology equity research analyst at Morgan Stanley, Inc. from 2000 to 2004 and Prudential Securities, Inc. from 1996 to 1999. She began her career as a financial analyst at BankAmerica Corporation. Ms. Loewy is a founding board member of the Global Genes Project and a member of the Steering Committee of the Forum for Collaborative Research in Rare Diseases. She is also a founding board member of the KCNQ2 Cure Alliance Foundation. Ms. Loewy currently serves on the boards of directors of, Zogenix, Inc., CymaBay Therapeutics Inc., Aptose Biosciences Inc. and PhaseBio Pharmaceuticals, Inc. Ms. Loewy holds a B.A. from the University of California, Berkeley, and a M.B.A./M.S. degree from Carnegie Mellon University.
- Bibhash Mukhopadhyay
-
Bibhash Mukhopadhyay自2018年2月以来一直担任我们的董事会成员。Mukhopadhyay博士目前担任New Enterprise Associates，Inc.的负责人，他自2015年10月起担任该职位。此前，Mukhopadhyay博士于2013年12月至2015年9月担任阿斯利康（AstraZeneca）的研究与开发子公司MedImmune，LLC的业务发展副总监。在此之前，他曾于2010年10月至2013年11月担任强生公司的经理。Mukhopadhyay博士在全印度医学科学研究所（All India Institute of Medical Sciences）获得生物化学与分子生物学学士学位，在Georg-August-Universit&228；T G&246；Ttingen获得神经科学硕士学位，在贝勒医学院获得生物医学科学博士学位。
Bibhash Mukhopadhyay has served as a member of our board of directors since February 2018. Dr. Mukhopadhyay currently serves as a principal at New Enterprise Associates, Inc., a position he has held since October 2015. Previously, Dr. Mukhopadhyay was an associate director of business development at MedImmune, LLC, the research and development subsidiary of AstraZeneca, from December 2013 to September 2015. Prior to that time, he served as a manager for Johnson & Johnson from October 2010 to November 2013. Dr. Mukhopadhyay received a B.S. in biochemistry and molecular biology from the All India Institute of Medical Sciences, a M.S. in neuroscience from Georg-August-Universität Göttingen and a Ph.D. in biomedical sciences from Baylor College of Medicine. - Bibhash Mukhopadhyay自2018年2月以来一直担任我们的董事会成员。Mukhopadhyay博士目前担任New Enterprise Associates，Inc.的负责人，他自2015年10月起担任该职位。此前，Mukhopadhyay博士于2013年12月至2015年9月担任阿斯利康（AstraZeneca）的研究与开发子公司MedImmune，LLC的业务发展副总监。在此之前，他曾于2010年10月至2013年11月担任强生公司的经理。Mukhopadhyay博士在全印度医学科学研究所（All India Institute of Medical Sciences）获得生物化学与分子生物学学士学位，在Georg-August-Universit&228；T G&246；Ttingen获得神经科学硕士学位，在贝勒医学院获得生物医学科学博士学位。
- Bibhash Mukhopadhyay has served as a member of our board of directors since February 2018. Dr. Mukhopadhyay currently serves as a principal at New Enterprise Associates, Inc., a position he has held since October 2015. Previously, Dr. Mukhopadhyay was an associate director of business development at MedImmune, LLC, the research and development subsidiary of AstraZeneca, from December 2013 to September 2015. Prior to that time, he served as a manager for Johnson & Johnson from October 2010 to November 2013. Dr. Mukhopadhyay received a B.S. in biochemistry and molecular biology from the All India Institute of Medical Sciences, a M.S. in neuroscience from Georg-August-Universität Göttingen and a Ph.D. in biomedical sciences from Baylor College of Medicine.
- Tyrell Rivers
-
Tyrell Rivers自2018年2月以来一直担任我们的董事会成员。Rivers博士是阿斯利康公司（AstraZeneca&8217；）企业发展集团的执行董事，负责战略股权投资、并购和撤资，自2014年以来一直担任该职位。在担任该职位之前，Rivers博士从2009年到2014年在MedImmune Ventures任职，在那里他专门从事生物技术投资，并从2001年到2007年在默克制药公司工作，在那里他担任各种技术和商业职务，责任越来越大。Rivers博士担任ADC Therapeutics SA、Armaron Bio Ltd、Cerapedics，Inc.和Corvidia Therapeutics，Inc.以及之前的G1治疗公司和PhaseBioPharmaceuticals，Inc.的董事。Rivers博士拥有麻省理工学院（Massachusetts Institute of Technology）的化学工程学士学位，得克萨斯大学奥斯汀分校（University of Texas at Austin）的化学工程博士学位，以及纽约大学斯特恩商学院（New York University Stern School of Business）的工商管理硕士学位。
Tyrell Rivers has served as a member of our board of directors since February 2018. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has held this position since 2014. Prior to this role, Dr. Rivers was at MedImmune Ventures from 2009 until 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he worked in various technical and business roles of increasing responsibility. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Cerapedics, Inc., and Corvidia Therapeutics, Inc. and previously G1 Therapeutics, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Rivers holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and an M.B.A. from the New York University Stern School of Business. - Tyrell Rivers自2018年2月以来一直担任我们的董事会成员。Rivers博士是阿斯利康公司（AstraZeneca&8217；）企业发展集团的执行董事，负责战略股权投资、并购和撤资，自2014年以来一直担任该职位。在担任该职位之前，Rivers博士从2009年到2014年在MedImmune Ventures任职，在那里他专门从事生物技术投资，并从2001年到2007年在默克制药公司工作，在那里他担任各种技术和商业职务，责任越来越大。Rivers博士担任ADC Therapeutics SA、Armaron Bio Ltd、Cerapedics，Inc.和Corvidia Therapeutics，Inc.以及之前的G1治疗公司和PhaseBioPharmaceuticals，Inc.的董事。Rivers博士拥有麻省理工学院（Massachusetts Institute of Technology）的化学工程学士学位，得克萨斯大学奥斯汀分校（University of Texas at Austin）的化学工程博士学位，以及纽约大学斯特恩商学院（New York University Stern School of Business）的工商管理硕士学位。
- Tyrell Rivers has served as a member of our board of directors since February 2018. Dr. Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for strategic equity investments, mergers and acquisitions, and divestments and has held this position since 2014. Prior to this role, Dr. Rivers was at MedImmune Ventures from 2009 until 2014 where he specialized in biotechnology investing, and at Merck & Co., Inc. from 2001 through 2007 where he worked in various technical and business roles of increasing responsibility. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Cerapedics, Inc., and Corvidia Therapeutics, Inc. and previously G1 Therapeutics, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Rivers holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from University of Texas at Austin, and an M.B.A. from the New York University Stern School of Business.
- Linda Tufts
-
Linda Tufts自2018年3月以来一直担任我们的董事会成员。Tufts女士自1989年以来一直担任Fletcher Spaght，Inc.的普通合伙人，该公司是一家为梦百合和技术公司提供咨询的公司。她也担任Fletcher Spaght Ventures公司（Fletcher Spaght Inc.的风险资本附属公司）的普通合伙人（2001年以来）。Tufts女士在麻省理工学院（Massachusetts Institute of Technology）获得人文与科学与电气工程学士学位，并在麻省理工学院（Massachusetts Institute of Technology）斯隆管理学院（Sloan School of Management）获得管理金融学硕士学位。
Linda Tufts has served as a member of our board of directors since March 2018. Ms. Tufts has served as a general partner of Fletcher Spaght, Inc., a consulting firm for healthcare and technology companies, since 1989. She also serves as the general partner of Fletcher Spaght Ventures, Fletcher Spaght Inc.’s venture capital affiliate, a position she has held since 2001. Ms. Tufts received an S.B. in humanities and science and in electrical engineering from the Massachusetts Institute of Technology and an S.M in management finance from the Sloan School of Management at the Massachusetts Institute of Technology. - Linda Tufts自2018年3月以来一直担任我们的董事会成员。Tufts女士自1989年以来一直担任Fletcher Spaght，Inc.的普通合伙人，该公司是一家为梦百合和技术公司提供咨询的公司。她也担任Fletcher Spaght Ventures公司（Fletcher Spaght Inc.的风险资本附属公司）的普通合伙人（2001年以来）。Tufts女士在麻省理工学院（Massachusetts Institute of Technology）获得人文与科学与电气工程学士学位，并在麻省理工学院（Massachusetts Institute of Technology）斯隆管理学院（Sloan School of Management）获得管理金融学硕士学位。
- Linda Tufts has served as a member of our board of directors since March 2018. Ms. Tufts has served as a general partner of Fletcher Spaght, Inc., a consulting firm for healthcare and technology companies, since 1989. She also serves as the general partner of Fletcher Spaght Ventures, Fletcher Spaght Inc.’s venture capital affiliate, a position she has held since 2001. Ms. Tufts received an S.B. in humanities and science and in electrical engineering from the Massachusetts Institute of Technology and an S.M in management finance from the Sloan School of Management at the Massachusetts Institute of Technology.
- Nancy J. Hutson
-
Nancy J. Hutson，女，博士，自2009年以来，她一直是董事会的成员。并且是Endo的研究与发展委员会的主席和Endo的薪酬委员会成员，提名和治理委员会和事务委员会成员。在2006年，她在25年的各种研究和领导职位之后，从Pfizer公司退休。最近她担任Pfizer全球研发高级副总裁，和Pfizer制药研发网站董事，被称为格罗顿/新伦敦实验室，在Pfizer制药公司最大的研发中心。在Pfizer，她带领4500个同事主要是科学家，管理预算超过10亿美元。目前她是Cubist Pharmaceuticals和 BioCryst Pharmaceuticals公司的董事，并服务于康涅狄格州的计划生育委员会。她获得Illinois Wesleyan University的一般生物学学士学位，以及Vanderbilt University的生理学和生物化学博士学位。
Nancy J. Hutson, Ph.D.,has been a member of the Board of Directors since the Company's inception in February 2014 and is Chairman of Endo's Compliance Committee and a member of Endo's Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. Pfizer in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a Director of BioCryst Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until January 2015 and from March 2009 until February 2014 was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT, which is dedicated to supporting the equestrian sport of dressage. - Nancy J. Hutson，女，博士，自2009年以来，她一直是董事会的成员。并且是Endo的研究与发展委员会的主席和Endo的薪酬委员会成员，提名和治理委员会和事务委员会成员。在2006年，她在25年的各种研究和领导职位之后，从Pfizer公司退休。最近她担任Pfizer全球研发高级副总裁，和Pfizer制药研发网站董事，被称为格罗顿/新伦敦实验室，在Pfizer制药公司最大的研发中心。在Pfizer，她带领4500个同事主要是科学家，管理预算超过10亿美元。目前她是Cubist Pharmaceuticals和 BioCryst Pharmaceuticals公司的董事，并服务于康涅狄格州的计划生育委员会。她获得Illinois Wesleyan University的一般生物学学士学位，以及Vanderbilt University的生理学和生物化学博士学位。
- Nancy J. Hutson, Ph.D.,has been a member of the Board of Directors since the Company's inception in February 2014 and is Chairman of Endo's Compliance Committee and a member of Endo's Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. Pfizer in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She currently is a Director of BioCryst Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until January 2015 and from March 2009 until February 2014 was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT, which is dedicated to supporting the equestrian sport of dressage.
高管简历
中英对照 | 中文 | 英文- Jonathan P. Mow
JonathanP.Mow自2014年9月以来一直担任我们的首席执行官兼董事会成员。他此前曾担任我们的首席商务官（2012年12月至2014年9月）。Mow先生在加州大学伯克利分校（University of California，Berkeley）获得机械工程学士学位，并在卡内基梅隆大学（Carnegie Mellon University）获得工商管理硕士学位。
Jonathan P. Mow has served as our Chief Executive Officer and a member of our board of directors since September 2014. He previously served as our Chief Business Officer from December 2012 to September 2014. Mr. Mow received a B.S. in mechanical engineering from the University of California, Berkeley and a M.B.A. from Carnegie Mellon University.- JonathanP.Mow自2014年9月以来一直担任我们的首席执行官兼董事会成员。他此前曾担任我们的首席商务官（2012年12月至2014年9月）。Mow先生在加州大学伯克利分校（University of California，Berkeley）获得机械工程学士学位，并在卡内基梅隆大学（Carnegie Mellon University）获得工商管理硕士学位。
- Jonathan P. Mow has served as our Chief Executive Officer and a member of our board of directors since September 2014. He previously served as our Chief Business Officer from December 2012 to September 2014. Mr. Mow received a B.S. in mechanical engineering from the University of California, Berkeley and a M.B.A. from Carnegie Mellon University.
- Susan Arnold
Susan Arnold自2010年10月以来一直担任我们临床前和化学，制造和控制的Vice President。Arnold博士在圣家大学（Holy Family University）获得生物学学士学位，在费城科学大学（University of Sciences）获得细胞生物学与生物技术硕士学位和细胞与分子生物学博士学位。
Susan Arnold has served as our Vice President of Preclinical and Chemistry, Manufacturing and Controls since October 2010. Dr. Arnold received a B.A. in biology from Holy Family University and a M.S. in cell biology and biotechnology and a Ph.D. in cell and molecular biology from the University of the Sciences in Philadelphia.- Susan Arnold自2010年10月以来一直担任我们临床前和化学，制造和控制的Vice President。Arnold博士在圣家大学（Holy Family University）获得生物学学士学位，在费城科学大学（University of Sciences）获得细胞生物学与生物技术硕士学位和细胞与分子生物学博士学位。
- Susan Arnold has served as our Vice President of Preclinical and Chemistry, Manufacturing and Controls since October 2010. Dr. Arnold received a B.A. in biology from Holy Family University and a M.S. in cell biology and biotechnology and a Ph.D. in cell and molecular biology from the University of the Sciences in Philadelphia.
- James Ballance
James Ballance自2014年10月以来一直担任我们的研究和科学事务Vice President。他曾于2013年1月至2014年10月担任我们的科学事务Vice President。Ballance博士获得了理学学士学位。威尔士大学应用生物学博士学位和布里斯托尔大学真菌分子遗传学博士学位。
James Ballance has served as our Vice President of Research and Scientific Affairs since October 2014. He previously served as our Vice President of Scientific Affairs from January 2013 to October 2014. Dr. Ballance received a B.Sc. in applied biology from the University of Wales and a Ph.D. in fungal molecular genetics from the University of Bristol.- James Ballance自2014年10月以来一直担任我们的研究和科学事务Vice President。他曾于2013年1月至2014年10月担任我们的科学事务Vice President。Ballance博士获得了理学学士学位。威尔士大学应用生物学博士学位和布里斯托尔大学真菌分子遗传学博士学位。
- James Ballance has served as our Vice President of Research and Scientific Affairs since October 2014. He previously served as our Vice President of Scientific Affairs from January 2013 to October 2014. Dr. Ballance received a B.Sc. in applied biology from the University of Wales and a Ph.D. in fungal molecular genetics from the University of Bristol.
- John Lee
John Lee自2018年10月起担任公司医药开发执行Vice President，自2020年1月起担任公司临时首席科学官。此前，他曾担任我们的高级副总裁，制药开发（2016年9月以来）。在加入我们之前，他在生物制药公司InfinityPharmaceuticals，Inc.担任了超过15年的责任和领导职务，最终于2006年至2016年9月担任高级副总裁，制药开发。Lee先生在麻省理工学院（Massachusetts Institute of Technology）获得材料科学与工程学士学位。
John Lee has served as our executive vice president, pharmaceutical development since October 2018 and our interim chief scientific officer since January 2020. Previously, he served as our senior vice president, pharmaceutical development since September 2016. Prior to joining us, he held roles of increasing responsibility and leadership over 15 years at Infinity Pharmaceuticals, Inc., a biopharmaceutical company, ultimately serving as senior vice president, pharmaceutical development from 2006 to September 2016. Mr. Lee received a B.A. in materials science and engineering from the Massachusetts Institute of Technology.- John Lee自2018年10月起担任公司医药开发执行Vice President，自2020年1月起担任公司临时首席科学官。此前，他曾担任我们的高级副总裁，制药开发（2016年9月以来）。在加入我们之前，他在生物制药公司InfinityPharmaceuticals，Inc.担任了超过15年的责任和领导职务，最终于2006年至2016年9月担任高级副总裁，制药开发。Lee先生在麻省理工学院（Massachusetts Institute of Technology）获得材料科学与工程学士学位。
- John Lee has served as our executive vice president, pharmaceutical development since October 2018 and our interim chief scientific officer since January 2020. Previously, he served as our senior vice president, pharmaceutical development since September 2016. Prior to joining us, he held roles of increasing responsibility and leadership over 15 years at Infinity Pharmaceuticals, Inc., a biopharmaceutical company, ultimately serving as senior vice president, pharmaceutical development from 2006 to September 2016. Mr. Lee received a B.A. in materials science and engineering from the Massachusetts Institute of Technology.
- Michael York
Michael York自2018年6月起担任公司发展和商业战略Vice President。在加入我们公司之前，York先生于2015年8月至2018年6月担任生物制药公司OrexigenTherapeutics，Inc.全球业务发展和联盟管理Vice President。他此前曾担任MKO Global Partners公司（生物制药战略咨询公司）的高级顾问（2015年1月至2015年8月）。从2013年7月到2014年12月，York先生担任Sente，Inc.的总裁兼首席执行官，这是一家药妆公司。York先生在圣地亚哥州立大学（San Diego State University）获得公共行政与经济学学士学位，并在雷德兰大学（University of Redlands）获得工商管理硕士学位。
Michael York has served as our Vice President of Corporate Development and Commercial Strategy since June 2018. Prior to joining our company, Mr. York served as the vice president of global business development and alliance management of Orexigen Therapeutics, Inc., a biopharmaceutical company, from August 2015 to June 2018. He previously served as a senior advisor for MKO Global Partners, L.P., a biopharmaceutical strategic advisory firm, from January 2015 to August 2015. From July 2013 to December 2014 Mr. York served as president and chief executive officer of Sente, Inc., a cosmeceutical company. Mr. York received a B.A. in public administration and economics from San Diego State University and a M.B.A. from the University of Redlands.- Michael York自2018年6月起担任公司发展和商业战略Vice President。在加入我们公司之前，York先生于2015年8月至2018年6月担任生物制药公司OrexigenTherapeutics，Inc.全球业务发展和联盟管理Vice President。他此前曾担任MKO Global Partners公司（生物制药战略咨询公司）的高级顾问（2015年1月至2015年8月）。从2013年7月到2014年12月，York先生担任Sente，Inc.的总裁兼首席执行官，这是一家药妆公司。York先生在圣地亚哥州立大学（San Diego State University）获得公共行政与经济学学士学位，并在雷德兰大学（University of Redlands）获得工商管理硕士学位。
- Michael York has served as our Vice President of Corporate Development and Commercial Strategy since June 2018. Prior to joining our company, Mr. York served as the vice president of global business development and alliance management of Orexigen Therapeutics, Inc., a biopharmaceutical company, from August 2015 to June 2018. He previously served as a senior advisor for MKO Global Partners, L.P., a biopharmaceutical strategic advisory firm, from January 2015 to August 2015. From July 2013 to December 2014 Mr. York served as president and chief executive officer of Sente, Inc., a cosmeceutical company. Mr. York received a B.A. in public administration and economics from San Diego State University and a M.B.A. from the University of Redlands.
- John Sharp
John Sharp是注册会计师，他于2007年4月加入该公司，担任我司财务部副总裁兼首席财务官。从2004年11月到2007年4月，Sharp先生担任Sequenom财务部副总裁，纳斯达克代码：SQNM，并从2005年10月开始担任其首席会计主任。从2000年8月到2004年11月，Sharp先生担任Diversa Corporation的会计主任，这是一家上市的生物技术公司。从1994年1月到2000年8月，Sharp先生在公共会计事务所普华永道会计师事务所（PricewaterhouseCoopers）任职，最后担任高级审计经理。他在圣地亚哥州立大学获得理学学士学位，并是一位注册会计师 （非执业），还是生物科学协会的财务官（Association of Bioscience Financial Officers）成员。
John Sharp has served as our Chief Financial Officer since April 2016. Prior to joining our company, Mr. Sharp served as chief financial officer of HUYA Bioscience International, LLC, a biopharmaceutical company, from March 2014 to December 2015. From April 2007 to February 2014 Mr. Sharp served as chief financial officer of Ligand Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Sharp received a B.S. in business administration from San Diego State University and is a certified public accountant.- John Sharp是注册会计师，他于2007年4月加入该公司，担任我司财务部副总裁兼首席财务官。从2004年11月到2007年4月，Sharp先生担任Sequenom财务部副总裁，纳斯达克代码：SQNM，并从2005年10月开始担任其首席会计主任。从2000年8月到2004年11月，Sharp先生担任Diversa Corporation的会计主任，这是一家上市的生物技术公司。从1994年1月到2000年8月，Sharp先生在公共会计事务所普华永道会计师事务所（PricewaterhouseCoopers）任职，最后担任高级审计经理。他在圣地亚哥州立大学获得理学学士学位，并是一位注册会计师 （非执业），还是生物科学协会的财务官（Association of Bioscience Financial Officers）成员。
- John Sharp has served as our Chief Financial Officer since April 2016. Prior to joining our company, Mr. Sharp served as chief financial officer of HUYA Bioscience International, LLC, a biopharmaceutical company, from March 2014 to December 2015. From April 2007 to February 2014 Mr. Sharp served as chief financial officer of Ligand Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Sharp received a B.S. in business administration from San Diego State University and is a certified public accountant.